A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung)

• Published in: Frontiers in pharmacology Vol. 12; p. 599598
• Main Authors: Heudobler, Daniel, Schulz, Christian, Fischer, Jürgen R, Staib, Peter, Wehler, Thomas, Südhoff, Thomas, Schichtl, Thomas, Wilke, Jochen, Hahn, Joachim, Lüke, Florian, Vogelhuber, Martin, Klobuch, Sebastian, Pukrop, Tobias, Herr, Wolfgang, Held, Swantje, Beckers, Kristine, Bouche, Gauthier, Reichle, Albrecht
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 16.03.2021
• Subjects: anakoinosis; biomodulation; checkpoint inhibition; nivolumab; NSCLC; Pharmacology; pioglitazone; priming; pioglitazone; biomodulation; NSCLC; nivolumab; checkpoint inhibition; metronomic chemotherapy, clarithromycin; anakoinosis

Most non-small cell lung cancers occur in elderly and frequently comorbid patients. Therefore, it is necessary to evaluate the efficacy of biomodulatory active therapy regimen, concertedly interfering with tumor-associated homeostatic pathways to achieve tumor control paralleled by modest toxicity p...